

ASX Announcement

6 March 2024

**BCAL APPOINTS STRATEGIC CEO TO LEAD BREASTEST™
2024 COMMERCIAL LAUNCH**

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that as part of its ramped-up commercialisation strategy the Company has appointed a new Australian based CEO, Shane Ryan to launch the company's new test BREASTEST™'s and drive the commercialisation process. Shane's tenure as CEO will commence on 2 April 2024.

Shane Ryan was initially appointed as the Company's Chief Operating Officer in Q1 FY24 (ASX announcement 31 October 2023) and has clearly demonstrated that he will be the right leader to take the organisation through market launch, and to ensure expansion and growth of the business. He has an excellent track record of success and brings a wealth of biotechnology product commercialisation experience from his prior role as Global SVP of Strategy & Innovation - Patient Access at GenesisCare.

In 2021 Shane brought to market a test for breast cancer patients which was successfully launched in Australia and is now available nationwide. Shane's commercial, product launch experience will be vital in ensuring a successful launch of BREASTEST™ in late 2024.

Current CEO, Dr John Hurrell will become a Non-Executive Director, and consultant to the Company providing ongoing advice in relation to the scientific product development, laboratory scaling, and commercial operations, as well as preparing for a subsequent launch in the USA.

BCAL Diagnostics Chair, Jayne Shaw said *"I am delighted to welcome Shane as our new CEO at this incredibly exciting and important time for the Company. The commercial launch of BREASTEST™ is fast approaching and Australia is our priority market in the short term. We have reached an inflection point and we are confident in Shane's ability to successfully execute our strategic growth strategy in the lead up to and beyond launch later this year."*

I would also like to express our thanks to John Hurrell who has made a significant contribution to BCAL. John's vast leadership experience in biotechnology, passion and drive for improving outcomes for cancer patients has been invaluable and I look forward to his continued involvement as a Director of and consultant to the Company."

These leadership changes follow the appointment of commercial leader David Darling as Non-Executive Director announced on 29 February 2024 and the formation of a highly credentialed Clinical Advisory Board in early FY24.

Jayne continued: *"It has been a priority of the Board to ensure BCAL is in the best possible position to execute its strategy and we have full confidence in the team to do so. BCAL has now cemented its position as a fast-emerging player in the breast cancer diagnostics sector and the next 12 months will be critical to ensuring we continue delivering at the same momentum."*

This announcement has been approved by the Board for release to the ASX.

ENDS**For further information:**

Jayne Shaw
Executive Chair
Jshaw@bcaldiagnostics.com

Guy Robertson
Chief Financial Officer
grobertson@bcaldiagnostics.com

Appendix - CEO Remuneration Package

The following information is provided in accordance with Listing Rule 3.16.4 in relation to the remuneration package of the incoming CEO, Shane Ryan.

Base salary \$350,000 plus statutory superannuation. Notice period of 3 months, or twelve months if position is termination through a change of control.

Short term incentive up to 50% of base salary on achievement of milestones. Long Term Incentive (LTI) for FY24, which includes the period employed as Chief Operation Officer, up to 2 million performance rights subject to achievement of milestones. LTI for FY25 to be determined, but not to be less than 3 million performance rights covering the financial years 2025 to 2027.

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% sensitivity and 85.5% specificity. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>